vs
Side-by-side financial comparison of Dermata Therapeutics, Inc. (DRMA) and Largo Inc. (LGO). Click either name above to swap in a different company.
Dermata Therapeutics, Inc. is the larger business by last-quarter revenue ($92.8K vs $87.6K, roughly 1.1× Largo Inc.). Largo Inc. runs the higher net margin — -59.3% vs -1853.3%, a 1794.0% gap on every dollar of revenue.
Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.
Largo Inc. is a Canada-based critical minerals producer focused on sustainable vanadium extraction and processing. It operates core production assets in Brazil, supplying high-purity vanadium products for steel manufacturing, grid-scale energy storage, and industrial clients across global markets.
DRMA vs LGO — Head-to-Head
Income Statement — Q3 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $92.8K | $87.6K |
| Net Profit | $-1.7M | $-52.0K |
| Gross Margin | — | — |
| Operating Margin | -1953.3% | — |
| Net Margin | -1853.3% | -59.3% |
| Revenue YoY | 531.8% | — |
| Net Profit YoY | 29.1% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $87.6K | ||
| Q2 25 | — | $54.4K | ||
| Q1 25 | — | $28.2K | ||
| Q3 24 | — | $100.7K | ||
| Q2 24 | — | $70.7K | ||
| Q1 24 | — | $42.2K | ||
| Q3 23 | $92.8K | — | ||
| Q2 23 | $31.1K | — |
| Q3 25 | — | $-52.0K | ||
| Q2 25 | — | $-40.0K | ||
| Q1 25 | — | $-18.3K | ||
| Q3 24 | — | $-18.7K | ||
| Q2 24 | — | $-3.9K | ||
| Q1 24 | — | $715 | ||
| Q3 23 | $-1.7M | — | ||
| Q2 23 | $-1.7M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | -1953.3% | — | ||
| Q2 23 | -5579.4% | — |
| Q3 25 | — | -59.3% | ||
| Q2 25 | — | -73.6% | ||
| Q1 25 | — | -64.9% | ||
| Q3 24 | — | -18.6% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | 1.7% | ||
| Q3 23 | -1853.3% | — | ||
| Q2 23 | -5479.4% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.4M | — |
| Total Assets | $7.3M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $6.6M | — | ||
| Q2 23 | $8.4M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $6.4M | — | ||
| Q2 23 | $8.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | $7.3M | — | ||
| Q2 23 | $8.7M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
